A German external quality survey of diagnostic microbiology of respiratory tract infections in patients with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 7, Issue 1, 2008, Pages 7-14

  Balke, Beate ^a   Schmoldt, Sabine ^b   Häußler, Susanne ^c   Suerbaum, Sebastian ^a   Heesemann, Jürgen ^b   Hogardt, Michael ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Clinical microbiology laboratories; Cystic fibrosis; External quality control programme

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERYTHROMYCIN; FOSFOMYCIN; GENTAMICIN; MEROPENEM; OXACILLIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BURKHOLDERIA; BURKHOLDERIA MULTIVORANS; CONTROLLED STUDY; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; GERMANY; INFECTION CONTROL; LABORATORY; MICROBIOLOGY; MORPHOTYPE; MULTIDRUG RESISTANCE; NONHUMAN; PATHOGENESIS; PILOT STUDY; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; QUESTIONNAIRE; RESPIRATORY TRACT INFECTION; SPECIES CULTIVATION; STAPHYLOCOCCUS AUREUS; STRAIN IDENTIFICATION;

EID: 38049039334     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2007.02.007     Document Type: Article

References (46)

1. FitzSimmons S.C. The changing epidemiology of cystic fibrosis. J Pediatr 122 (1993) 1-9
2. Rosenstein B.J., and Zeitlin P.L. Cystic fibrosis. Lancet 351 (1998) 277-282
3. Lyczak J.B., Cannon C.L., and Pier G.B. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15 (2002) 194-222
4. Gilligan P.H. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4 (1991) 35-51
5. Burns J.L., Emerson J., Stapp J.R., et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 27 (1998) 158-163
6. Schmoldt S., Latzin P., Heesemann J., Griese M., Imhof A., and Hogardt M. Clonal analysis of Inquilinus limosus isolates from six cystic fibrosis patients and specific serum antibody response. J Med Microbiol 55 (2006) 1425-1433
7. Coenye T., Goris J., Spilker T., Vandamme P., and LiPuma J.J. Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov. J Clin Microbiol 40 (2002) 2062-2069
8. Beringer P.M., and Appleman M.D. Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features. Curr Opin Pulm Med 6 (2000) 545-550
9. Jorgensen I.M., Johansen H.K., Frederiksen B., et al. Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr Pulmonol 36 (2003) 439-446
10. Regelmann W.E., Elliott G.R., Warwick W.J., and Clawson C.C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 141 (1990) 914-921
11. Canton R., Cobos N., de Gracia J., et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 11 (2005) 690-703
12. Hoiby N., Frederiksen B., and Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 4 Suppl 2 (2005) 49-54
13. Kahl B., Herrmann M., Everding A.S., et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 177 (1998) 1023-1029
14. Haussler S., Tummler B., Weissbrodt H., Rohde M., and Steinmetz I. Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin Infect Dis 29 (1999) 621-625
15. Chapin K.C., and Doern G.V. Selective media for recovery of Haemophilus influenzae from specimens contaminated with upper respiratory tract microbial flora. J Clin Microbiol 17 (1983) 1163-1165
16. Wright R.M., Moore J.E., Shaw A., et al. Improved cultural detection of Burkholderia cepacia from sputum in patients with cystic fibrosis. J Clin Pathol 54 (2001) 803-805
17. Henry D., Campbell M., McGimpsey C., et al. Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 37 (1999) 1004-1007
18. Gilligan P.H., Gage P.A., Bradshaw L.M., Schidlow D.V., and DeCicco B.T. Isolation medium for the recovery of Pseudomonas cepacia from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 22 (1985) 5-8
19. Vanlaere E., Hansraj F., Vandamme P.A., and Govan J.R. Growth in Stewart's medium is a simple, rapid and inexpensive screening tool for the identification of Burkholderia cepacia complex. J Cyst Fibros 5 2 (May 2006) 137-139 [Epub 2006 Jan 4]
20. Saiman L., and Siegel J. Cystic Fibrosis Foundation. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 31 (2003) 1-62
21. Hogardt M., Haeussler S., Balke B., et al. Mikrobiologisch-infektiologische Qualitätsstandards (MIQ): Atemwegsinfektionen bei Mukoviszidose (2006), Urban & Fischer
22. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. 5th ed. (2000) [Wayne PA]
23. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2003;6th ed. Wayne, PA.
24. Deutsches Institut für Normierung e.V. Methoden zur Empfindlichkeitsprüfung von mikrobiellen Krankheitserregern gegen Chemotherapeutika (DIN 58940). 2002; Beuth Verlag, Berlin.
25. Kresken M., Hafner D., and Winnemöller J. Interpretation der Testergebnisse mit Fosfomycin im Agar-Diffusionstest. Der Mikrobiologe 15 (2005) 191-198
26. Jones A.M., Dodd M.E., and Govan J.R. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 59 (2004) 948-951
27. Kipp F., Kahl B.C., Becker K., et al. Evaluation of two chromogenic agar media for recovery and identification of Staphylococcus aureus small-colony variants. J Clin Microbiol 43 (2005) 1956-1959
28. Doern G.V., and Brogden-Torres B. Optimum use of selective plated media in primary processing of respiratory tract specimens from patients with cystic fibrosis. J Clin Microbiol 30 (1992) 2740-2742
29. Saiman L., Mehar F., Niu W.W., et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 23 (1996) 532-537
30. Maduri-Traczewski M., L'Heureux C., Escalona L., Macone A., and Goldmann D. Facilitated detection of antibiotic-resistant Pseudomonas in cystic fibrosis sputum using homogenized specimens and antibiotic-containing media. Diagn Microbiol Infect Dis 5 (1986) 299-305
31. Van Dalfsen J.M., Stapp J.R., Phelps C., Stewart P., and Burns J.L. Comparison of two culture methods for detection of tobramycin-resistant gram-negative organisms in the sputum of patients with cystic fibrosis. J Clin Microbiol 40 (2002) 26-30
32. Tablan O.C., Carson L.A., Cusick L.B., Bland L.A., Martone W.J., and Jarvis W.R. Laboratory proficiency test results on use of selective media for isolating Pseudomonas cepacia from simulated sputum specimens of patients with cystic fibrosis. J Clin Microbiol 25 (1987) 485-487
33. Kiska D.L., Kerr A., Jones M.C., et al. Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol 34 (1996) 886-891
34. Zhou J., Garber E., Desai M., and Saiman L. Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosis. J Clin Microbiol 44 (2006) 1547-1549
35. Chernish R.N., and Aaron S.D. Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr Opin Pulm Med 9 (2003) 509-515
36. Burns J.L., Saiman L., Whittier S., et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 38 (2000) 1818-1822
37. Saiman L., Burns J.L., Whittier S., Krzewinski J., Marshall S.A., and Jones R.N. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol 37 (1999) 2987-2991
38. Burns J.L., Saiman L., Whittier S., et al. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis 39 (2001) 257-260
39. Balke B., Hoy L., Weissbrodt H., and Haussler S. Comparison of the Micronaut Merlin automated broth microtiter system with the standard agar dilution method for antimicrobial susceptibility testing of mucoid and nonmucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 23 (2004) 765-771
40. Haussler S., Ziesing S., Rademacher G., Hoy L., and Weissbrodt H. Evaluation of the Merlin, Micronaut system for automated antimicrobial susceptibility testing of Pseudomonas aeruginosa and Burkholderia species isolated from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 22 (2003) 496-500
41. Smith A.L., Fiel S.B., Mayer-Hamblett N., Ramsey B., and Burns J.L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123 (2003) 1495-1502
42. Aaron S.D., Vandemheen K.L., Ferris W., Fergusson D., Tullis E., Haase D., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366 (2005) 463-471
43. Zhou J., Chen Y., Tabibi S., Alba L., Garber E., and Saiman L. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother (2006) [Epub ahead of print]
44. Govan J.R. Multidrug-resistant pulmonary infection in cystic fibrosis-what does 'resistant' mean?. J Med Microbiol 55 (2006) 1615-1617
45. Smyth A. Multiresistant pulmonary infection in cystic fibrosis-prevention is better than cure. Lancet 366 (2005) 433-435
46. VanDevanter D.R., and Van Dalfsen J.M. How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?. Pediatr Pulmonol 39 (2005) 504-506